首页|依达拉奉右莰醇联合丁苯酞氯化钠注射液对急性脑梗死患者血清单核细胞趋化蛋白-1、内皮素-1表达的影响

依达拉奉右莰醇联合丁苯酞氯化钠注射液对急性脑梗死患者血清单核细胞趋化蛋白-1、内皮素-1表达的影响

扫码查看
目的 探讨依达拉奉右莰醇联合丁苯酞氯化钠注射液对急性脑梗死患者血清单核细胞趋化蛋白-1(MCP-1)、内皮素-1(ET-1)表达及动脉粥样硬化斑块的影响。方法 选取河北省邯郸市中医院 2020 年 12 月至 2022 年 8 月收治的急性脑梗死患者 140 例,按随机数字表法分为联合组和对照组,各 70 例。两组患者均予丁苯酞氯化钠注射液,联合组患者加用依达拉奉右莰醇注射液,均治疗 14 d。结果 联合组总有效率为 91。43%,显著高于对照组的 68。57%(P<0。05)。治疗后,两组患者的颈动脉内中膜厚度、斑块面积、美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(MRS)评分及血清MCP-1、ET-1、丙二醛、超氧化物歧化酶水平均显著降低(P<0。05),且联合组均显著低于对照组(P<0。05);联合组和对照组患者治疗期间不良反应发生率相当(12。86%比14。29%,P>0。05)。结论 依达拉奉右莰醇联合丁苯酞氯化钠注射液治疗急性脑梗死的临床疗效良好,可有效改善患者的神经功能缺损情况、颈动脉粥样硬化斑块稳定性及内皮功能,降低氧化应激水平,提高生活质量,且安全性良好。
Effect of Edaravone and Dexborneol Combined with Butylphthalide and Sodium Chloride Injection on the Expression of Serum Monocyte Chemoattractant Protein-1 and Endothelin-1 in Patients with Acute Cerebral Infarction
Objective To investigate the effect of edaravone and dexborneol combined with Butylphthalide and Sodium Chloride Injection on the expression of serum monocyte chemoattractant protein-1(MCP-1)and endothelin-1(ET-1),and the atherosclerotic plaque in patients with acute cerebral infarction(ACI).Methods A total of 140 patients with ACI admitted to the Handan Hospital of Traditional Chinese Medicine from December 2020 to August 2022 were selected and randomly divided into the combined group and the control group by the random number table method,with 70 cases in each group.The patients in the two groups were given Butylphthalide and Sodium Chloride Injection,on this basis,the patients in the combined group were treated with Edaravone and Dexborneol Injection.Both groups were treated for 14 d.Results The total effective rate in the combined group was 91.43%,which was significantly higher than 68.57%in the control group(P<0.05).After treatment,the carotid intima-media thickness,plaque area,National Institutes of Health Stroke Scale(NIHSS)score,modified Rankin Scale(MRS)score,and the levels of serum MCP-1,ET-1,malondialdehyde(MDA),and superoxide dismutase(SOD)in the two groups significantly reduced(P<0.05),and those in the combined group were significantly lower than those in the control group(P<0.05).During treatment,the incidence of adverse reactions in the combined group was comparable to that in the control group(12.86%vs.14.29%,P>0.05).Conclusion Edaravone and dexborneol combined with Butylphthalide and Sodium Chloride Injection in the treatment of acute cerebral infarction has good clinical efficacy and safety,which can effectively improve the neurological defect,the stability of carotid atherosclerotic plaque and the endothelial function,reduce the oxidative stress level,and improve the quality of life.

acute cerebral infarctionButylphthalide and Sodium Chloride Injectionedaravone and dexborneolmonocyte chemoattractant protein-1endothelin-1oxidative stressatherosclerotic plaque

杨华英、崔娅晖、郑连红、王琮民

展开 >

河北省邯郸市中医院,河北 邯郸 056000

河北工程大学附属医院,河北 邯郸 056000

急性脑梗死 丁苯酞氯化钠注射液 依达拉奉右莰醇 单核细胞趋化蛋白-1 内皮素-1 氧化应激 动脉粥样硬化斑块

河北省科技计划项目

17277714D

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(9)
  • 19